Questions For Our Attorneys?
We stand for our clients.Call us today: (855) 264-6270

David Miceli

Shareholders

One Court Street
Alton, Illinois
62002
  RETURN TO ATTORNEY SEARCH

Practice Areas:

Bar and Court Admissions:

  • Florida, 1992
  • Alabama, 1992
  • Georgia, 1994
  • U.S. District Court Northern, Central & Southern Districts of Alabama, 1992
  • U.S. District Court Northern & Central Districts of Georgia, 1994
  • U.S. Court of Appeals, 11th Circuit, 1999

Recognition:

  • Test Case Trial Counsel, In re: Nutraquest, Inc. Litigation, USDC-NJ
  • Member/Coordinating Counsel. In re: Nutraquest, Inc. Litigation, USDC-NJ
  • Mediation Liaison Counsel, In re: Nutraquest, Inc. Litigation, USDC-NJ
  • PPA MDL, Discovery Team (Perrigo, Inc.); USDC-WA
  • Founder, Cox-2 Litigation Group (AAJ)
  • May 2003 Presentation, “VIOXX, Should We Litigate This Drug?”; AAJ Emerging Drug Litigation, Chicago, IL
  • July 2003, Founded Cox-2 Litigation Group; AAJ Annual Meeting, Atlanta, GA
  • July 2004, Moderator/Panelist, VIOXX: An Update on Discovery and Status of the Litigation; AAJ Annual Meeting, Boston, MA
  • Spring 2003 Presentation: How to Market for Mass Tort Cases; Mass Torts Made Perfect, Las Vegas, NV

Representative Experience:

Affiliations:

  • American Association for Justice
  • Baycol Litigation Group (AAJ)
  • PPA Litigation Group (AAJ)
  • Ephedra Litigation Group (AAJ)
  • Founder, Cox-2 Litigation Group (AAJ)

Education:

  • Cumberland School of Law, Samford University, J.D. 1991
  • Auburn University, B.S. Major:Business Economics, 1985

David Miceli joined the firm’s pharmaceutical litigation department Of Counsel in 2006. Based in Georgia, David has practiced law for twenty years and specializes in complex pharmaceutical and medical device litigation.

He has extensive experience litigating mass tort cases, including Vioxx, Bextra, Celebrex, PPA, Ephedra, Baycol, Trasylol, Rezulin, Reglan and Chantix. He has recovered millions of dollars on behalf of thousands of consumers injured while taking drugs that were touted as safe, but were proved harmful or fatal to their users. David was lead trial counsel in a Nutraquest test case that ultimately led to settlements exceeding $35 million for more than 150 plaintiffs.*

Currently, David serves on the national Plaintiff Steering Committee for the Chantix Multi-District Litigation (MDL). He served on the discovery team for the Bextra MDL, including having a leading role in expert discovery in both the MDL & the state consolidated litigation in New York City.

David has also served on the Plaintiff’s Steering Committee for the Trasylol MDL, including a leading role in both corporate factual and expert discovery. In addition to his federal court work, he is currently involved in numerous pharmaceutical cases in the state courts of Pennsylvania, West Virginia and Rhode Island.

Background and Experience

David graduated from Cumberland School of Law at Samford University in 1991. He worked for 10 years on the defense in medical malpractice and other serious injury cases, including pharmaceutical matters. David made the switch to the plaintiff’s side of litigation in 2001, and soon afterward, filed the first action in the country against Merck & Co., Inc., over its blockbuster drug Vioxx.

David is the founding member of the American Association for Justice’s (formerly ATLA) Cox-2 Litigation Group. In addition, David has authored several articles on pharmaceutical torts and is regularly asked to give presentations on relevant pharmaceutical topics at industry conferences.

* Please note that recovery results vary per client. The recovery amounts in each case reflect the specific facts of that case. Further, recovery amounts in past cases are not a guarantee of future results.